Loading
A phase 1/2 trial of PM8002 in small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07325136 by Bristol-Myers Squibb, with 240 participants planned, started 2026-02-03 and due to reach its primary completion in 2029-04-23. Interventions recorded: BMS-986525, Pumitamig. Conditions listed: Relapsed/Refractory Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, Bristol Myers Squibb.
Shares PM8002, Small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
Shares PM8002, Small-cell lung cancer.
Shares PM8002, Small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/